This website uses cookies to enhance the user experience.
A

ACD PHARMACEUTICALS AS979 455 518

Research
Limited company
Lofoten Bio Centre Storeidøya 60 8370 LEKNES, Norge

ACD PHARMACEUTICALS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
27 years
since Feb 12, 1998
Type
Limited company
VAT registered
Yes
Number of employees
10

Ownership

Number of shares and share classes
300,000
1 share class
Total number of shareholders
2
companies
Belongs to group of

Financials

Total operating income 2024
24,666,319
NOK
Annual total result 2024
-967,122
NOK
Total equity 2024
13,983,767
NOK
Last update: Jul 29, 2025

Management

Board

NameRoleShares
Board Member-
Chairman-

Others

NameRoleShares
N
NORDNORSK REVISJON AS
Auditor-

Top 10 individual shareholders

NameRoleShares
-
99.67 %
indirectly
Last update: Jun 1, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
N
NORDLY HOLDING AS
Ordinary shares
299,000
99.67 %
P
PCK INVEST AS
Ordinary shares
1,000
0.33 %
Last update: Jun 2, 2025

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -651,655
    Employees: 0

Financials

in NOK

Summary

Year2024202320222021
Total operating income
24,666,319
29,422,858
26,850,380
12,705,836
Annual Total Result
-967,122
3,652,953
-12,270,640
1,144,517
Total assets
75,444,325
32,902,332
24,282,655
16,204,229
Total liabilities
61,460,558
17,731,018
10,208,523
3,170,698
Total equity
13,983,767
15,171,315
14,074,132
13,033,531

P&L

Year2024202320222021
Total operating income
24,666,319
29,422,858
26,850,380
12,705,836
Total operating costs
28,490,726
24,574,688
42,807,484
11,420,493
Operating result
-3,824,407
4,848,169
-15,957,104
1,285,343
Financial income/costs
-717,345
-468,716
-36,400
-25,605
Profit before tax
-4,541,752
4,379,453
-15,993,504
1,259,738
Total tax & extraordinary income/cost
-3,574,630
726,500
-3,722,864
115,221
Annual Total Result
-967,122
3,652,953
-12,270,640
1,144,517

Balance overview

Year2024202320222021
Total fixed assets
48,325,564
25,452,376
1,103,000
3,672,740
Total current assets
27,118,761
7,449,956
23,179,655
12,531,489
Total assets
75,444,325
32,902,332
24,282,655
16,204,229
Short term debt
61,460,558
17,695,963
5,098,973
3,170,698
Long term debt
0
35,055
5,109,550
0
Total liabilities
61,460,558
17,731,018
10,208,523
3,170,698
Contributed capital
13,390,815
13,611,241
13,611,241
300,000
Retained earnings
592,952
1,560,074
462,891
12,733,531
Total equity
13,983,767
15,171,315
14,074,132
13,033,531
Total equity and liabilities
75,444,325
32,902,332
24,282,655
16,204,229

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology